Index
Grant: Novartis — Cryptosporidiosis Challenge Trial (Coefficient Giving → Novartis)
Verdictconfirmed95%
1 check · 4/9/2026Deterministic match: grantee, amount, date matched in source snapshot (2714 rows)
Our claim
entire record- Name
- Novartis — Cryptosporidiosis Challenge Trial
- Amount
- $2,500,000
- Currency
- USD
- Date
- October 2024
- Notes
[Scientific Research] Open Philanthropy recommended a grant of $2,500,000 over two years to Novartis to support a Phase IIa challenge trial of a new drug, ED1048, for the treatment of cryptosporidiosis. Cryptosporidiosis is caused by the Cryptosporidium parasite. The parasite is… expand
[Scientific Research] Open Philanthropy recommended a grant of $2,500,000 over two years to Novartis to support a Phase IIa challenge trial of a new drug, ED1048, for the treatment of cryptosporidiosis. Cryptosporidiosis is caused by the Cryptosporidium parasite. The parasite is widespread globally and highly resistant to sanitizers used for cleaning drinking water. The disease can be fatal in small children, the elderly, and immunocompromised people. This falls within our focus area of scientific research.
Source evidence
1 src · 1 checkconfirmed95%deterministic-row-match · 4/9/2026
- Name
- Novartis — Cryptosporidiosis Challenge Trial
- Grantee
- Novartis
- Focus Area
- Scientific Research
- Amount
- $2,500,000.00
- Date
- October 2024
- Description
- Open Philanthropy recommende
NoteDeterministic match: grantee, amount, date matched in source snapshot (2714 rows)
Case № 7_IZW0438kFiled 4/9/2026Confidence 95%